Company IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 USD | 0.00% | 0.00% | -87.85% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 05 | North American Morning Briefing : Investors on -2- | DJ |
Business Summary
Number of employees: 160
Managers
Managers | Title | Age | Since |
---|---|---|---|
John D. Hoekman
FOU | Founder | 43 | 07-12-31 |
Sheena Aurora
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Youmans
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
Sarah Wille
HRO | Human Resources Officer | - | 18-12-31 |
Lynn Gold
LAW | General Counsel | 67 | 18-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Nelson
BRD | Director/Board Member | 60 | 17-01-31 |
Ali Satvat
BRD | Director/Board Member | 46 | 18-12-06 |
Diane Wilfong
BRD | Director/Board Member | 62 | 19-09-16 |
David Allison
BRD | Director/Board Member | 42 | 19-05-31 |
John D. Hoekman
FOU | Founder | 43 | 07-12-31 |
Darren Cline
BRD | Director/Board Member | 59 | 23-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,900,031 | 21,120,240 ( 88.37 %) | 0 | 88.37 % |
Company contact information
Impel Pharmaceuticals, Inc.
201 Elliott Avenue West Suite 260
98119, Seattle
+206 568 1466
http://impelpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IMPL Stock
- Company IPI Legacy Liquidation Co